The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., Hill M. A., Fuleihan G. El- Hajj, Gnudi L., Kim Y-B., Larsson S. C., et al. (2022).  Metabolism, Clinical and Experimental: seventy years young and growing.. Metabolism. 155333.
Polyzos, S. A., Singhellakis P. N., Naot D., Adamidou F., Malandrinou F. C., Anastasilakis A. D., et al. (2014).  Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene).. J Clin Endocrinol Metab. 99(3), 703-7.
Polyzos, S. A., Zeglinas C., Artemaki F., Doulberis M., Kazakos E., Katsinelos P., et al. (2018).   infection and esophageal adenocarcinoma: a review and a personal view.. Ann Gastroenterol. 31(1), 8-13.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2013).  Serum sclerostin levels following treatment with parathyroid hormone.. J Endocrinol Invest. 36(4), 280.
Polyzos, S. A., & Goulis D. G. (2024).  Menopause and metabolic dysfunction-associated steatotic liver disease.. Maturitas. 108024.
Polyzos, S. A., Anastasilakis A. D., Bratengeier C., Woloszczuk W., Papatheodorou A., & Terpos E. (2012).  Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.. Osteoporos Int. 23(3), 1171-6.
Polyzos, S. A., Kita M., Efstathiadou Z., Poulakos P., Slavakis A., Sofianou D., et al. (2008).  Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules.. J Cancer Res Clin Oncol. 134(9), 953-60.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z., Litsas I., Kita M., Panagiotou A., et al. (2010).  Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.. J Bone Miner Metab. 28(3), 314-9.
Polyzos, S. A. (2017).  Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease.. Minerva Endocrinol. 42(2), 89-91.
Polyzos, S. A., & Mantzoros C. S. (2020).  Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).. Metabolism. 154318.
Polyzos, S. A., Papaefthymiou A., Doulberis M., Mavridoglou G., & Kountouras J. (2021).  Helicobacter pylori infection and diabetes mellitus.. Diabetes Metab Syndr. 15(3), 845-846.
Polyzos, S. A., Papaefthymiou A., Doulberis M., & Kountouras J. (2023).  Nonalcoholic fatty liver disease test: an external validation cohort.. Hormones (Athens).
Polyzos, S. A., & Anastasilakis A. D. (2011).  Rare potential complications of thyroid fine needle biopsy.. Hippokratia. 15(2), 116-9.
Polyzos, S. A., Kountouras J., Mantzoros C. S., Polymerou V., & Katsinelos P. (2017).  Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.. Diabetes Obes Metab. 19(12), 1805-1809.
Polyzos, S. A., & Kountouras J. (2015).  Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity.. Helicobacter. 20(6), 405-9.
Polyzos, S. A., & Goulas A. (2020).  Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing.. Med Hypotheses. 110379.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Paget's disease of bone: emphasis on treatment with zoledronic acid.. Expert Rev Endocrinol Metab. 4(5), 423-434.
Polyzos, S. A., & Mantzoros C. S. (2018).  Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead.. Metabolism. 78, A4-A9.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Litsas I., Kita M., Arsos G., et al. (2011).  Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.. Osteoporos Int. 22(1), 363-7.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2016).  Adipokines in nonalcoholic fatty liver disease.. Metabolism. 65(8), 1062-79.
Polyzos, S. A., & Kountouras J. (2012).  Visual vignette. Anaplastic thyroid carcinoma.. Endocr Pract. 18(1), 108.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.. Curr Med Chem.
Polyzos, S. A., & Kountouras J. (2016).  Homocysteine in nonalcoholic steatohepatitis: A reply.. Eur J Intern Med. 35, e40-e41.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., & Terpos E. (2023).  Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications.. Hepatobiliary Pancreat Dis Int.
Polyzos, S. A., Kountouras J., Goulas A., & Duntas L. (2020).  Selenium and selenoprotein P in nonalcoholic fatty liver disease.. Hormones (Athens). 19(1), 61-72.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.